Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1249/JSR.0000000000000567 | DOI Listing |
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
J Man Manip Ther
February 2025
Center for Rehabilitation Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
J Orthop Case Rep
December 2024
Department of Orthopedic, Sancheti Institute for Orthopaedics and Rehabilitation, Pune, Maharashtra, India.
J Nutr
December 2024
Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Int J Environ Res Public Health
November 2024
Institute of Sports Science, University of the Bundeswehr Munich, 85579 Neubiberg, Germany.
Urban green exercise offers substantial physical and mental health benefits, especially in urban environments with limited natural access. This study analyzes the demand for urban year-round green exercise under various meteorological conditions. Using a primary empirical research design, data were collected from 408 active participants in Germany through an online survey.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!